NASDAQ:HSCS Heart Test Laboratories (HSCS) Stock Price, News & Analysis → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free HSCS Stock Alerts $0.09 0.00 (0.00%) (As of 05/9/2024 ET) Add Compare Share Share Today's Range$0.09▼$0.0950-Day Range$0.09▼$0.1852-Week Range$0.09▼$1.32Volume928,168 shsAverage Volume2.63 million shsMarket Capitalization$5.89 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Heart Test Laboratories alerts: Email Address Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About Heart Test Laboratories Stock (NASDAQ:HSCS)Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.Read More HSCS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HSCS Stock News HeadlinesApril 30, 2024 | msn.comResearchers develop genetic test for early detection of high cardiovascular riskApril 29, 2024 | abcnews.go.comFDA brings lab tests under federal oversight in bid to improve accuracy and safetyMay 9, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.April 24, 2024 | globenewswire.comHeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECGApril 13, 2024 | msn.comRoche Diagnostics India launches heart failure test for diabetics in IndiaApril 4, 2024 | msn.comEarly coronary disease, impaired heart function found in asymptomatic people with HIVApril 4, 2024 | msn.comThe Importance of Regular Lipid Profile Testing For Cardiovascular WellnessApril 2, 2024 | globenewswire.comHeartSciences to Present at the LD Micro Invitational XIV ConferenceMay 9, 2024 | Priority Gold (Ad)The 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.March 26, 2024 | globenewswire.comHeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative PatientsMarch 15, 2024 | finanznachrichten.deHeart Test Laboratories, Inc.: HeartSciences Reports Third Quarter Fiscal 2024 Financial ResultsMarch 14, 2024 | benzinga.comRecap: Heart Test Laboratories Q3 EarningsMarch 14, 2024 | finance.yahoo.comHeartSciences Reports Third Quarter Fiscal 2024 Financial ResultsMarch 14, 2024 | globenewswire.comHeartSciences Reports Third Quarter Fiscal 2024 Financial ResultsMarch 12, 2024 | morningstar.comHeart Test Laboratories IncMarch 12, 2024 | finance.yahoo.comHeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 DiabetesMarch 12, 2024 | globenewswire.comHeartSciences' Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 DiabetesMarch 6, 2024 | investorplace.comWhy Is Heart Test Laboratories (HSCS) Stock Down 21% Today?March 6, 2024 | globenewswire.comHeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet TechnologyFebruary 26, 2024 | globenewswire.comHeartSciences Adds Key Advisor to its Scientific Advisory BoardFebruary 24, 2024 | forbes.comBest At-Home Blood Tests: A 2024 GuideFebruary 12, 2024 | finance.yahoo.comHeartSciences Expands its Scientific Advisory BoardFebruary 2, 2024 | msn.com'Heart-on-a-chip' to test chemotherapies and other cancer drugs for heart toxicityFebruary 1, 2024 | msn.comPromising heart drugs identified by cutting-edge combo of machine learning, human learningDecember 20, 2023 | investing.comHeart Test Laboratories Unt (HSCS) Earnings Dates & ReportsDecember 15, 2023 | finanznachrichten.deHeart Test Laboratories, Inc.: HeartSciences Reports Second Quarter Fiscal 2024 Financial ResultsNovember 21, 2023 | benzinga.comThinking about buying stock in Devon Energy, NextEra Energy, Datadog, Heart Test Laboratories, or Artivion?See More Headlines Receive HSCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heart Test Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today5/09/2024Next Earnings (Estimated)7/16/2024Fiscal Year End4/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical appliances & supplies Sub-IndustryN/A Current SymbolNASDAQ:HSCS CUSIPN/A CIK1468492 Webheartsciences.com Phone682-237-7781FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,350,000.00 Net MarginsN/A Pretax Margin-33,636.84% Return on Equity-381.92% Return on Assets-134.17% Debt Debt-to-Equity RatioN/A Current Ratio5.09 Quick Ratio4.70 Sales & Book Value Annual Sales$18,600.00 Price / Sales316.88 Cash FlowN/A Price / Cash FlowN/A Book Value$0.02 per share Price / Book4.50Miscellaneous Outstanding Shares65,562,000Free Float63,779,000Market Cap$5.89 million OptionableNot Optionable Beta3.40 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Andrew Simpson (Age 54)CEO, President & Chairman of the Board of Directors Comp: $264.14kMs. Danielle Watson (Age 41)CFO & Treasurer Comp: $188.75kMr. Mark T. Hilz (Age 65)COO, Secretary & Director Comp: $263.61kKey CompetitorsPredictive OncologyNASDAQ:POAINanoVibronixNASDAQ:NAOVAyala PharmaceuticalsNASDAQ:ADXSBIOLASENASDAQ:BIOLPortage BiotechNASDAQ:PRTGView All Competitors HSCS Stock Analysis - Frequently Asked Questions How have HSCS shares performed in 2024? Heart Test Laboratories' stock was trading at $0.1710 at the start of the year. Since then, HSCS stock has decreased by 47.4% and is now trading at $0.0899. View the best growth stocks for 2024 here. Are investors shorting Heart Test Laboratories? Heart Test Laboratories saw a increase in short interest in April. As of April 15th, there was short interest totaling 599,600 shares, an increase of 343.2% from the March 31st total of 135,300 shares. Based on an average trading volume of 1,920,000 shares, the short-interest ratio is currently 0.3 days. Approximately 1.1% of the shares of the company are sold short. View Heart Test Laboratories' Short Interest. When is Heart Test Laboratories' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 16th 2024. View our HSCS earnings forecast. How were Heart Test Laboratories' earnings last quarter? Heart Test Laboratories, Inc. (NASDAQ:HSCS) issued its quarterly earnings results on Thursday, March, 14th. The company reported ($0.03) earnings per share for the quarter. The business had revenue of $0.02 million for the quarter. When did Heart Test Laboratories IPO? Heart Test Laboratories (HSCS) raised $9 million in an initial public offering on Wednesday, June 15th 2022. The company issued 1,800,000 shares at a price of $4.50-$5.50 per share. The Benchmark Company served as the underwriter for the IPO. How do I buy shares of Heart Test Laboratories? Shares of HSCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HSCS) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithGold Set to EXPLODE!Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersUrgent Nvidia WarningAltimetryObama’s Forever Term [exposed]Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heart Test Laboratories, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
